Mylan Pharmaceuticals Inc. v. Acorda Therapeutics Inc.
Petition for certiorari denied on January 9, 2017
Issue: Whether the mere filing of an abbreviated new drug application by a generic pharmaceutical manufacturer is sufficient to subject the manufacturer to specific personal jurisdiction in any state where it might someday market the drug.
| Date | Proceedings and Orders (key to color coding) |
|---|
| Sep 19 2016 | Petition for a writ of certiorari filed. (Response due October 21, 2016) |
| Oct 4 2016 | Consent to the filing of amicus curiae briefs, in support of either party or of neither party, received from counsel for the respondents Acorda Therapeutics, Inc., and Pharma Ireland Limited. |
| Oct 6 2016 | Order extending time to file response to petition to and including November 21, 2016, for all respondents. |
| Oct 21 2016 | Brief amicus curiae of Generic Pharmaceutical Association filed. |
| Nov 21 2016 | Brief of respondent AstraZeneca AB in opposition filed. |
| Nov 21 2016 | Brief of respondents Acorda Therapeutics, Inc. and Alkermes Pharma Ireland Limited in opposition filed. |
| Dec 7 2016 | DISTRIBUTED for Conference of January 6, 2017. |
| Dec 7 2016 | Reply of petitioners Mylan Pharmaceuticals, et al. filed. (Distributed) |
| Dec 12 2016 | Rescheduled. |
| Dec 21 2016 | DISTRIBUTED for Conference of January 6, 2017. |
| Jan 9 2017 | Petition DENIED. Justice Alito took no part in the consideration or decision of this petition. |
